Usha Ravi
Research Subjects
Usha Ravi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Harikrishna Choudary Ponnam
Department of Internal Medicine, Summa Health System, Akron, OH 44304, USA
2 shared publications - Kunal Sonavane
Willis Knighton Health, Bossier City, LA 71111, USA
2 shared publications - Pallavi Shirsat
Minden Medical Center, Minden, LA 71055, USA
2 shared publications - Rahul Kashyap
Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA, USA
2 shared publications - Saketh Parsi
Department of Internal Medicine, Ascension Seton Medical Center Austin, Austin, TX 78705, USA
2 shared publications - Venkata Sushma Chamarthi
Department of Pediatrics, Valley Children’s Healthcare, Madera, CA 93636, USA
2 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 72
Congenital hypothyroidism with preserved fifth digits in SMARCA4-related Coffin-Siris syndrome: a case report
Background: Coffin-Siris syndrome (CSS) is an uncommon genetic condition that is generally associated with developmental delay, craniofacial dysmorphism, hypertrichosis, and hypoplasia or aplasia of the fifth digit. Genetic variations in genes that encode components of the SWI/SNF chromatin-remodeling complex, such as SMARCA4, are known to cause CSS with variable phenotype expression. The expanded use of genotype-first methods has contributed to the broadening of the awareness of non-classical presentations. Case Description: We present a case of a 10-year-old girl who presented for genetic evaluation because of developmental delay, anxiety with nonverbal behavioral predominance, cleft palate repair, microcephaly, and short stature. At the age of 3 months, she was diagnosed with congenital hypothyroidism and has been on constant levothyroxine. Examination physical examination showed hypertrichosis, mild craniofacial dysmorphism, and benign joint hypermobility, intact fifth digits and nails. A heterozygous variant in SMARCA4 was identified using trio exome sequencing (c.3315G>T) which revealed a de novo heterozygous variant. A variant of uncertain significance (VUS) in AP1S2 was also identified. Past cytogenetic and molecular testing had eliminated other genetic causes of syndromic developmental delay. The multidisciplinary management incorporated surgery revision of cleft palate repair, endocrine treatment, pharmacologic treatment of anxiety, behavioral treatment, and educational assistance. Conclusions: The case presents a SMARCA4-associated phenotype of the CSS with intact fifth digits and with congenital hypothyroidism. This association has not been described in the literature to our knowledge. The findings reinforce the significance of genetic testing in children with complex patterns of development even without the traditional physical manifestations and propose that endocrine features can be considered further in SMARCA4-related CSS.
- 1 March 2026
- Published by AME Publishing Company in AME Case Reports
- Vol. 10, 72
Open AccessCongenital hypothyroidism with preserved fifth digits in SMARCA4-related Coffin-Siris syndrome: a case report
Background: Coffin-Siris syndrome (CSS) is an uncommon genetic condition that is generally associated with developmental delay, craniofacial dysmorphism, hypertrichosis, and hypoplasia or aplasia of the fifth digit. Genetic variations in genes that encode components of the SWI/SNF chromatin-remodeling complex, such as SMARCA4, are known to cause CSS with variable phenotype expression. The expanded use of genotype-first methods has contributed to the broadening of the awareness of non-classical presentations. Case Description: We present a case of a 10-year-old girl who presented for genetic evaluation because of developmental delay, anxiety with nonverbal behavioral predominance, cleft palate repair, microcephaly, and short stature. At the age of 3 months, she was diagnosed with congenital hypothyroidism and has been on constant levothyroxine. Examination physical examination showed hypertrichosis, mild craniofacial dysmorphism, and benign joint hypermobility, intact fifth digits and nails. A heterozygous variant in SMARCA4 was identified using trio exome sequencing (c.3315G>T) which revealed a de novo heterozygous variant. A variant of uncertain significance (VUS) in AP1S2 was also identified. Past cytogenetic and molecular testing had eliminated other genetic causes of syndromic developmental delay. The multidisciplinary management incorporated surgery revision of cleft palate repair, endocrine treatment, pharmacologic treatment of anxiety, behavioral treatment, and educational assistance. Conclusions: The case presents a SMARCA4-associated phenotype of the CSS with intact fifth digits and with congenital hypothyroidism. This association has not been described in the literature to our knowledge. The findings reinforce the significance of genetic testing in children with complex patterns of development even without the traditional physical manifestations and propose that endocrine features can be considered further in SMARCA4-related CSS.
- Open Access
- 20 November 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1700475
21st century innovations in pediatrics
21 st -century innovations in pediatrics have made remarkable advancements in enhancing patient care and making care accessible even in remote areas. This abstract provides a concise summary of the latest innovations in pediatrics. Recent innovations in Pediatrics include Telemedicine, where people can connect with specialists using electronic technology, helping those in remote areas access timely care. Advances in neonatal care have effectively created solutions for several conditions, thereby reducing morbidity and mortality. The use of wearable technology has shown promise in several areas, including promoting a healthy lifestyle, monitoring physiological parameters, facilitating treatment for various conditions, and post-operative monitoring. AI in diagnostics is already aiding in earlier diagnosis and triage in emergency rooms, facilitating the diagnosis of certain genetic syndromes, and enabling the earlier detection of neonatal sepsis, among other areas in pediatrics. Innovations in pediatric vaccinations, utilizing novel technology, have made vaccines less painful and led to the development of new vaccines for conditions such as RSV, one of the viruses causing respiratory distress in newborns during the winter. Mental Health care in pediatrics has helped in reducing stigma and improving access to care for behavioral health counselling for conditions like depression and anxiety, using a smartphone app. Pediatric surgery has seen substantial progress in minimally invasive procedures, which help reduce post-operative pain, minimize tissue damage, decrease recovery time, and minimize scarring. Pediatric care now emphasizes addressing social determinants of health like housing, income, emotional support, food insecurity, and stressors in a child's life, which helps in timely referrals.
- 20 November 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1700475
Open Access21st century innovations in pediatrics
21 st -century innovations in pediatrics have made remarkable advancements in enhancing patient care and making care accessible even in remote areas. This abstract provides a concise summary of the latest innovations in pediatrics. Recent innovations in Pediatrics include Telemedicine, where people can connect with specialists using electronic technology, helping those in remote areas access timely care. Advances in neonatal care have effectively created solutions for several conditions, thereby reducing morbidity and mortality. The use of wearable technology has shown promise in several areas, including promoting a healthy lifestyle, monitoring physiological parameters, facilitating treatment for various conditions, and post-operative monitoring. AI in diagnostics is already aiding in earlier diagnosis and triage in emergency rooms, facilitating the diagnosis of certain genetic syndromes, and enabling the earlier detection of neonatal sepsis, among other areas in pediatrics. Innovations in pediatric vaccinations, utilizing novel technology, have made vaccines less painful and led to the development of new vaccines for conditions such as RSV, one of the viruses causing respiratory distress in newborns during the winter. Mental Health care in pediatrics has helped in reducing stigma and improving access to care for behavioral health counselling for conditions like depression and anxiety, using a smartphone app. Pediatric surgery has seen substantial progress in minimally invasive procedures, which help reduce post-operative pain, minimize tissue damage, decrease recovery time, and minimize scarring. Pediatric care now emphasizes addressing social determinants of health like housing, income, emotional support, food insecurity, and stressors in a child's life, which helps in timely referrals.
- Open Access
- 11 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 8001
Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Atrial Fibrillation Recurrences After Catheter Ablation in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis
Background/Objectives: Sodium glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated a reduction in heart failure (HF) hospitalizations in HF patients and decreased recurrence of atrial fibrillation (AF), including in those who have undergone catheter ablation (CA). The effects of SGLT2i are likely due to suppression of the renin–angiotensin–aldosterone system, reduction in oxidative stress with subsequent improvement in myocardial efficiency, and attenuation of cardiac remodeling. We aim to present the effects of SGLT2i on AF recurrence in patients who have undergone CA for AF. Methods: This is a systematic review and meta-analysis of randomized controlled trials (RCTs) and retrospective studies evaluating the effect of SGLT2i on AF recurrence following CA compared with non-SGLT2i. The primary outcome was the recurrence of AF by the final follow-up reported in each study. Secondary outcomes include AF recurrence by the first follow-up within 12 to 24 months and follow-up intervals (6, 12, 18, 24, and 36 to 42 months) post-ablation, multivariate risk of AF recurrence, and the effect on left atrial diameter (LAD) (less than 45 mm vs. greater than or equal to 45 mm). For risk of bias (ROB) analysis, the NIH ROB and Cochrane ROB2 tool were used. All statistical, heterogeneity, and sensitivity analyses were conducted using Cochrane Review Manager. A random-effect model was employed for all pooled statistical analyses. Results: A total of nine studies, two RCTs and seven retrospective studies, were included (N = 6874) for the primary outcome. Compared to non-SGLT2i (N = 3693), SGLT2i (N = 3181) significantly decreased AF recurrence by the final follow-up (OR = 0.62; 95% CI: 0.45–0.85; p = 0.008). For secondary outcomes, SGLT2i significantly reduced AF recurrence by the first follow-up within 12 to 24 months post-ablation (OR = 0.58; p = 0.0001) and by the different follow-up periods, 6-month (OR = 0.53; p = 0.02), 12-month (OR = 0.56; p = 0.0001), 18-month (OR = 0.55; p = 0.01), and 24-month (OR = 0.60; p = 0.12) follow-up periods. On the other hand, by 36 to 42 months, SGLT2i was associated with increased risk of AF recurrence (OR = 1.41; p = 0.004). Conclusions: We conclude that SGLT2i demonstrated a reduction in AF recurrence following CA, particularly by 12 to 18 months post-ablation.
- 11 November 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (22) , 8001
Open AccessEffects of Sodium Glucose Co-Transporter 2 Inhibitors on Atrial Fibrillation Recurrences After Catheter Ablation in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis
Background/Objectives: Sodium glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated a reduction in heart failure (HF) hospitalizations in HF patients and decreased recurrence of atrial fibrillation (AF), including in those who have undergone catheter ablation (CA). The effects of SGLT2i are likely due to suppression of the renin–angiotensin–aldosterone system, reduction in oxidative stress with subsequent improvement in myocardial efficiency, and attenuation of cardiac remodeling. We aim to present the effects of SGLT2i on AF recurrence in patients who have undergone CA for AF. Methods: This is a systematic review and meta-analysis of randomized controlled trials (RCTs) and retrospective studies evaluating the effect of SGLT2i on AF recurrence following CA compared with non-SGLT2i. The primary outcome was the recurrence of AF by the final follow-up reported in each study. Secondary outcomes include AF recurrence by the first follow-up within 12 to 24 months and follow-up intervals (6, 12, 18, 24, and 36 to 42 months) post-ablation, multivariate risk of AF recurrence, and the effect on left atrial diameter (LAD) (less than 45 mm vs. greater than or equal to 45 mm). For risk of bias (ROB) analysis, the NIH ROB and Cochrane ROB2 tool were used. All statistical, heterogeneity, and sensitivity analyses were conducted using Cochrane Review Manager. A random-effect model was employed for all pooled statistical analyses. Results: A total of nine studies, two RCTs and seven retrospective studies, were included (N = 6874) for the primary outcome. Compared to non-SGLT2i (N = 3693), SGLT2i (N = 3181) significantly decreased AF recurrence by the final follow-up (OR = 0.62; 95% CI: 0.45–0.85; p = 0.008). For secondary outcomes, SGLT2i significantly reduced AF recurrence by the first follow-up within 12 to 24 months post-ablation (OR = 0.58; p = 0.0001) and by the different follow-up periods, 6-month (OR = 0.53; p = 0.02), 12-month (OR = 0.56; p = 0.0001), 18-month (OR = 0.55; p = 0.01), and 24-month (OR = 0.60; p = 0.12) follow-up periods. On the other hand, by 36 to 42 months, SGLT2i was associated with increased risk of AF recurrence (OR = 1.41; p = 0.004). Conclusions: We conclude that SGLT2i demonstrated a reduction in AF recurrence following CA, particularly by 12 to 18 months post-ablation.
- Open Access
- 11 September 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16
The impact of ultra-processed foods on pediatric health
- 11 September 2025
- Published by Elsevier in Obesity Pillars
- Vol. 16
Open AccessThe impact of ultra-processed foods on pediatric health